BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Celyad (Formally Known as Cardio3 BioSciences) 

Parc de L’Alliance
9, Boulevard de France
Braine - L’Alleud    1420  Belgium
Phone: 32-2-790-35-30 Fax: 32-2-790-35-35


SEARCH JOBS




Industry
Biotechnology






 Company News
Celyad Announces First Quarter 2015 Business Update 5/19/2015 10:50:58 AM
Celyad Says It Might Go Shopping With $115 Million IPO As CAR-T Roars 5/18/2015 1:20:19 PM
Cardio3 Biosciences Announces Results Of Annual Shareholder Assembly 2015 And Confirmation Of Name Change To Celyad 5/5/2015 10:27:15 AM
Cardio3 BioSciences Becomes Celyad 4/15/2015 1:03:38 PM
Cardio3 BioSciences Enrolls First Patient in Phase I Trial For NKG2D CAR T-Cell 4/13/2015 10:48:23 AM
Edison Publishes Research Note On Cardio3 BioSciences, US IPO Intended 4/13/2015 7:04:27 AM
BioLife Solutions, Inc. (BLFS.OB) CryoStor Cell Preservation Media Embedded In Cardio3 BioSciences' Phase III Clinical Trials Of C-Cure Cell Therapy For Congestive Heart Failure 4/9/2015 6:18:58 AM
Cardio3 BioSciences Receives USPTO Notice Of Allowance For First U.S. Patent Broadly Covering TCR-Deficient T-Cells Engineered To Express A Chimeric Antigen Receptor 4/8/2015 5:57:32 AM
Cardio3 BioSciences Receives USPTO Notice Of Allowance For First U.S. Patent Broadly Covering Tcr-Deficient T-Cells Engineered To Express A Chimeric Antigen Receptor 4/7/2015 10:35:53 AM
Cardio3 BioSciences Announces Intention To Conduct A Registered Public Offering In The United States 4/1/2015 10:46:41 AM
1234567